Abstract
After more than 60 years of the first successful bone marrow transplant (BMT) by D.E. Thomas for the treatment of hematological malignant diseases and more than 46 years since the first bone marrow transplant by Alberto Restrepo-Mesa in Medellin-Colombia for the treatment of a female triplet patient with paroxysmal nocturnal hemoglobinuria and aplastic anemia, in Colombia only around 750 bone marrow transplants are performed annually.
 With the experience accumulated during these years by each one of us, the León XIII Clinic of the Universidad de Antioquia began the hematopoietic stem cell transplantation (HSCT) program for adults in 2014. In this review, we report some clinical lessons drawn from the different phases of the HSCT in 109 adult patients with hematological malignancies. The progression-free survival (PFS) and the five-year overall survival (OS) were for autologous stem cell transplantation (ASCT) (87% and 70%), allogeneic stem cell transplantation (Allo SCT) (50% and 40%) and haploidentical stem cell transplantation (Haplo SCT) (25% and 18%) respectively.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
